Natixis’s CONMED CNMD Stock Holding History

Natixis’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Buy	+69,000	New	+$2.48M	0.01%	612
2025 Q2	–	Sell	-35,334	Closed	-$2.14M	–	1055
2025 Q1	$2.14M	Sell	35,334 -78,666	-69%	-$5.07M	0.01%	420
2024 Q4	$7.8M	Buy	114,000 +104,250	+1,069%	+$7.27M	0.05%	278
2024 Q3	$701K	Buy	+9,750	New	+$688K	﹤0.01%	584
2024 Q1	–	Sell	-58,700	Closed	-$6.43M	–	1035
2023 Q4	$6.43M	Buy	58,700 +3,900	+7%	+$403K	0.05%	275
2023 Q3	$5.53M	Buy	54,800 +34,858	+175%	+$4.01M	0.04%	280
2023 Q2	$2.71M	Buy	+19,942	New	+$2.43M	0.02%	379
2022 Q4	–	Sell	-102,750	Closed	-$8.24M	–	1132
2022 Q3	$8.24M	Buy	+102,750	New	+$9.69M	0.04%	303
2017 Q4	–	Sell	-4,187	Closed	-$220K	–	891
2017 Q3	$220K	Buy	+4,187	New	+$210K	﹤0.01%	1080

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Natixis's CNMD Position: Q2 2026 in Review

Natixis opened a new position in CONMED (CNMD) in Q2 2026: 69,000 shares worth $2.26M. The stake represents 0.01% of the portfolio and ranks #612 among its holdings. This is a return to the name: Natixis previously reported a position in CNMD as recently as Q1 2025.

Natixis first reported a position in CNMD in Q3 2017 and has held it in 9 quarters since. The position peaked at $8.24M in Q3 2022. 247 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

Natixis held 69,000 shares of CONMED worth $2.26M as of Q2 2026.
CONMED was a new Natixis position in Q2 2026.
CONMED made up 0.01% of Natixis's portfolio in Q2 2026, its #612 holding.
Natixis first reported a position in CONMED in Q3 2017 and has held it in 9 quarters since.
Natixis's CONMED position peaked at $8.24M in Q3 2022.
247 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.